Latest newsView all

After a wider approval, Ionis expects a year of Tryngolza sales to match one 2025 quarter

Ionis now expects about $50 million of Tryngolza sales in 2026, about half its earlier forecast, it said on Nov. 9. Its quarterly report says most prescriptions still need a medical exemption while insurers set coverage.

KeyVex News··6 min readFact-checked against 8 public records
KeyVex News··6 min readFact-checked against 8 public records
IONS$39.42▲ 1.6%Close, Nov. 6. Prices from Tiingo.
The short versionTap to readTap to close
  1. Ionis lowered Tryngolza's list price to $40,000 on April 1, before approval for a much larger group of patients. Its sales now turn on how fast that group starts treatment.
  2. The FDA approved Tryngolza on June 24 for a condition Ionis says more than 3 million Americans have. In the next quarter, the first full one, it sold $9 million.
  3. That is under a fifth of the $50 million it sold in 2025's last quarter, when approved only for a rare disease, and under a third of the $32 million a year earlier.
  4. Ionis still sets its goal at more than $3 billion a year at the drug's peak. Asked on the call how long that would take, it said it had not given a timeline.
  5. Next: Arrowhead says it is on schedule to ask the FDA by the end of 2026 to approve its rival drug for the same patients. Ionis gives its 2027 forecast in February.

The forecast: Ionis Pharmaceuticals cut its 2026 sales forecast for Tryngolza, its triglyceride drug, to about $50 million from $100 million to $110 million, it said before the market opened on Nov. 9. It said the launch for a wider group of patients was ramping "more gradually than expected."8-K About $50 million is what the drug sold in the last three months of 2025 alone.8-K In afternoon trading on Nov. 9, at 1:17 p.m., its stock was down 24% at $29.95.IONS

The price cut: Until June, Tryngolza was approved only for familial chylomicronemia syndrome, or FCS. FCS is a rare form of severe hypertriglyceridemia, or sHTG: blood fats high enough to raise the risk of pancreatitis attacks.8-K For FCS alone, it sold $108 million in 2025.8-K In April, Ionis lowered Tryngolza's wholesale list price "to address the sHTG population prior to receiving FDA approval," its quarterly report says.10-Q The new price, $40,000, took effect April 1, an executive said on the call.Call Ionis says more than 3 million Americans have sHTG. The FDA approved Tryngolza for it on June 24.8-K

Why it matters: In July, Ionis said Tryngolza was on track for $100 million to $110 million this year.8-K Through September it had sold $41 million.8-K Its finance chief, Beth Hougen, said on the call that Ionis now expects to break even on cash flow in 2029, not 2028, citing late-stage trial setbacks as well as the slower Tryngolza launch.Call8-K

Ionis's stock and Tryngolza's key datesDaily close, Dec. 1, 2025 to Nov. 6, 2026 ▼ 51.9%Show chartHide chart
Ionis's stock and Tryngolza's key datesDaily close as traded, Dec. 1, 2025, to Nov. 6, 2026, the last close before the forecast cut. Numbered dots mark the story's key dates, not what moved the stock. Switch ranges or compare with the S&P 500.
IONS
Ionis Pharmaceuticals · Nasdaq
Nasdaq 100S&P 500
Filings
Story90D1Y5Y10Y
IONSS&P 500 (rebased)1News in this story
Congress BuyCongress SellInsider BuyInsider SellForm 1448-KLobbying
Loading the chart…
Daily closes as traded · Close Prices from Tiingo.comColored dots are filings · White numbered dots are the news in this story · IONS on KeyVex
  1. 1Feb. 25, 2026 Tryngolza's 2025 sales: $108 million. $50 million of it came in the fourth quarter, all for the rare disease FCS.
  2. 2April 29, 2026 Ionis forecasts $100 million to $110 million for 2026. It also raises its peak sales goal for Tryngolza to more than $3 billion a year. The list price cut took effect April 1.
  3. 3June 24, 2026 The FDA approves Tryngolza for severe hypertriglyceridemia. Ionis says more than 3 million people in the U.S. have the condition.
  4. 4July 29, 2026 Second-quarter sales: $5 million. Ionis says it is on track for its $100 million to $110 million forecast.
  5. 5Nov. 6, 2026 Last close before the forecast cut: $39.42. On Nov. 9 Ionis cut its 2026 Tryngolza forecast to about $50 million. This chart ends at the Nov. 6 close.
View the data (236 trading days)
DateCloseDay change
2026-11-06$39.42+1.6%
2026-11-05$38.80−3.4%
2026-11-04$40.15−0.7%
2026-11-03$40.42−2.0%
2026-11-02$41.24−5.2%
2026-10-30$43.52−2.0%
2026-10-29$44.39−1.1%
2026-10-28$44.90+2.1%
2026-10-27$43.96+1.2%
2026-10-26$43.42+1.1%
2026-10-23$42.93−2.2%
2026-10-22$43.91−0.8%
2026-10-21$44.27−2.5%
2026-10-20$45.40+2.3%
2026-10-19$44.38+3.4%
2026-10-16$42.94−2.7%
2026-10-15$44.12+3.3%
2026-10-14$42.70+0.8%
2026-10-13$42.38−3.0%
2026-10-12$43.67−3.6%
2026-10-09$45.28+4.6%
2026-10-08$43.30−1.9%
2026-10-07$44.16+0.4%
2026-10-06$44.00+1.1%
2026-10-05$43.50−0.1%
2026-10-02$43.54−1.0%
2026-10-01$44.00−1.5%
2026-09-30$44.65−2.7%
2026-09-29$45.89+0.7%
2026-09-28$45.57+2.4%
2026-09-25$44.50+1.6%
2026-09-24$43.81−0.3%
2026-09-23$43.93−4.0%
2026-09-22$45.75+1.9%
2026-09-21$44.90+1.0%
2026-09-18$44.44−4.9%
2026-09-17$46.75+4.3%
2026-09-16$44.84−5.1%
2026-09-15$47.25−8.1%
2026-09-14$51.44−5.1%
2026-09-11$54.21−2.6%
2026-09-10$55.65−0.7%
2026-09-09$56.02−1.2%
2026-09-08$56.71−2.4%
2026-09-04$58.09−0.1%
2026-09-03$58.13−5.2%
2026-09-02$61.33+2.4%
2026-09-01$59.88−0.8%
2026-08-31$60.36−1.1%
2026-08-28$61.05−2.2%
2026-08-27$62.43−1.5%
2026-08-26$63.36−0.3%
2026-08-25$63.57+2.5%
2026-08-24$62.04+3.9%
2026-08-21$59.74+1.7%
2026-08-20$58.76−3.4%
2026-08-19$60.80+2.0%
2026-08-18$59.62+1.7%
2026-08-17$58.63+2.4%
2026-08-14$57.24+2.5%
2026-08-13$55.87−1.2%
2026-08-12$56.53+2.0%
2026-08-11$55.42−2.7%
2026-08-10$56.94+0.7%
2026-08-07$56.56+3.8%
2026-08-06$54.49+0.6%
2026-08-05$54.19−1.6%
2026-08-04$55.07+1.1%
2026-08-03$54.49+5.3%
2026-07-31$51.77−2.8%
2026-07-30$53.28−1.4%
2026-07-29$54.04−2.3%
2026-07-28$55.30−1.2%
2026-07-27$55.96−1.0%
2026-07-24$56.55+1.2%
2026-07-23$55.87+3.4%
2026-07-22$54.01+1.2%
2026-07-21$53.39+0.8%
2026-07-20$52.95−2.6%
2026-07-17$54.39−0.5%
2026-07-16$54.65−0.1%
2026-07-15$54.73−0.4%
2026-07-14$54.93−3.2%
2026-07-13$56.75−2.6%
2026-07-10$58.25−9.4%
2026-07-09$64.27−23.9%
2026-07-08$84.46−2.2%
2026-07-07$86.33+3.8%
2026-07-06$83.18+1.7%
2026-07-02$81.80+3.3%
2026-07-01$79.19−0.1%
2026-06-30$79.29−1.7%
2026-06-29$80.69−0.6%
2026-06-26$81.18+3.6%
2026-06-25$78.34+2.4%
2026-06-24$76.52+0.7%
2026-06-23$75.99+0.1%
2026-06-22$75.89+2.4%
2026-06-18$74.12−0.3%
2026-06-17$74.31+1.7%
2026-06-16$73.09−1.2%
2026-06-15$73.96+0.9%
2026-06-12$73.28−0.7%
2026-06-11$73.82+0.7%
2026-06-10$73.32−1.7%
2026-06-09$74.58+1.4%
2026-06-08$73.54−1.3%
2026-06-05$74.48−0.9%
2026-06-04$75.13+1.8%
2026-06-03$73.82+1.2%
2026-06-02$72.97−3.2%
2026-06-01$75.38−1.5%
2026-05-29$76.50−1.1%
2026-05-28$77.33+1.1%
2026-05-27$76.49+0.6%
2026-05-26$76.07+0.7%
2026-05-22$75.56−0.3%
2026-05-21$75.78+1.0%
2026-05-20$75.06+1.7%
2026-05-19$73.84+1.8%
2026-05-18$72.52−2.3%
2026-05-15$74.23−1.9%
2026-05-14$75.68−2.5%
2026-05-13$77.60+2.3%
2026-05-12$75.83+0.6%
2026-05-11$75.38−0.4%
2026-05-08$75.71−0.4%
2026-05-07$76.02−1.1%
2026-05-06$76.85+2.1%
2026-05-05$75.25−0.3%
2026-05-04$75.45+0.2%
2026-05-01$75.28+0.7%
2026-04-30$74.76−0.1%
2026-04-29$74.83+4.2%
2026-04-28$71.78−0.6%
2026-04-27$72.23−1.4%
2026-04-24$73.27−1.1%
2026-04-23$74.09−1.0%
2026-04-22$74.83+0.1%
2026-04-21$74.78−0.1%
2026-04-20$74.87−1.1%
2026-04-17$75.71+0.6%
2026-04-16$75.26−2.0%
2026-04-15$76.82+0.1%
2026-04-14$76.76+2.4%
2026-04-13$74.95−0.3%
2026-04-10$75.17−1.6%
2026-04-09$76.43+1.9%
2026-04-08$74.98+1.5%
2026-04-07$73.89−0.6%
2026-04-06$74.33−0.6%
2026-04-02$74.79−0.5%
2026-04-01$75.13+0.1%
2026-03-31$75.09+3.5%
2026-03-30$72.52+0.5%
2026-03-27$72.15−2.8%
2026-03-26$74.24+2.1%
2026-03-25$72.70+4.3%
2026-03-24$69.68−1.6%
2026-03-23$70.79−0.3%
2026-03-20$70.99−0.5%
2026-03-19$71.32−0.5%
2026-03-18$71.67−0.9%
2026-03-17$72.330.0%
2026-03-16$72.34+1.6%
2026-03-13$71.19−1.6%
2026-03-12$72.34−3.3%
2026-03-11$74.79−1.1%
2026-03-10$75.66+0.4%
2026-03-09$75.36+1.8%
2026-03-06$74.04−1.5%
2026-03-05$75.16−5.4%
2026-03-04$79.45+1.0%
2026-03-03$78.66−4.0%
2026-03-02$81.96+1.0%
2026-02-27$81.15+0.7%
2026-02-26$80.60−0.4%
2026-02-25$80.93−5.3%
2026-02-24$85.45+1.0%
2026-02-23$84.60+1.7%
2026-02-20$83.150.0%
2026-02-19$83.14+1.1%
2026-02-18$82.22+1.1%
2026-02-17$81.36+0.9%
2026-02-13$80.60−1.4%
2026-02-12$81.78−3.0%
2026-02-11$84.35+0.1%
2026-02-10$84.29−0.6%
2026-02-09$84.79−2.0%
2026-02-06$86.50+3.6%
2026-02-05$83.48−1.8%
2026-02-04$84.99+0.5%
2026-02-03$84.59+1.8%
2026-02-02$83.07+0.5%
2026-01-30$82.67−1.4%
2026-01-29$83.88+2.4%
2026-01-28$81.92−0.3%
2026-01-27$82.14+1.4%
2026-01-26$81.00+0.9%
2026-01-23$80.28−1.8%
2026-01-22$81.79+3.0%
2026-01-21$79.44+2.5%
2026-01-20$77.53+1.6%
2026-01-16$76.33−1.1%
2026-01-15$77.21−2.1%
2026-01-14$78.87−0.8%
2026-01-13$79.48−2.7%
2026-01-12$81.66+1.7%
2026-01-09$80.30−1.5%
2026-01-08$81.54−2.0%
2026-01-07$83.17+2.1%
2026-01-06$81.49+3.8%
2026-01-05$78.53−1.4%
2026-01-02$79.67+0.7%
2025-12-31$79.11+0.2%
2025-12-30$78.97−1.3%
2025-12-29$79.98+0.1%
2025-12-26$79.93−0.9%
2025-12-24$80.65+0.4%
2025-12-23$80.33−1.2%
2025-12-22$81.34+2.2%
2025-12-19$79.57+2.5%
2025-12-18$77.63+0.7%
2025-12-17$77.08−1.6%
2025-12-16$78.37−1.7%
2025-12-15$79.76−1.3%
2025-12-12$80.82+2.1%
2025-12-11$79.14+0.6%
2025-12-10$78.63−0.3%
2025-12-09$78.86−3.3%
2025-12-08$81.51−0.2%
2025-12-05$81.68−0.2%
2025-12-04$81.810.0%
2025-12-03$81.84+0.7%
2025-12-02$81.31−0.8%
2025-12-01$81.99

On Nov. 9, after this chart ends, Ionis traded at $29.95 at 1:17 p.m., down 24% from the Nov. 6 close.IONS Source: Tiingo end-of-day closes, as traded, via KeyVex.

Tryngolza's sales, quarter by quarter

Tryngolza's sales rose every quarter of 2025, from $6 million in the first to $50 million in the fourth.8-K8-K8-K8-K They fell to $27 million in the first quarter of 2026, which Ionis said reflected strong demand, offset by a lower net price.8-K In the second quarter, sales were $5 million, and in the third, $9 million.8-K8-K

Ionis cut the price before the approval to line up with insurers' 2027 contracts and ease access once the drug was approved, its quarterly report says.10-Q

Tryngolza's sales by quarter, in millions of dollarsU.S. net product sales. The list price was cut to $40,000 on April 1, 2026; the sHTG approval came June 24.
View the data
QuarterTryngolza net salesNote
Q1 2025$6MFrom the comparison column of Ionis's first-quarter 2026 release
Q2 2025$19MFrom the comparison column of Ionis's second-quarter 2026 release
Q3 2025$32MFrom the comparison column of Ionis's third-quarter 2026 release
Q4 2025$50MIonis's full-year 2025 release
Q1 2026$27MIonis's first-quarter 2026 release
Q2 2026$5MList price cut to $40,000 on April 1
Q3 2026$9MFirst full quarter after the June 24 approval for sHTG

Quarters are Ionis's own rounded figures; the four 2025 quarters add to $107 million against the $108 million full-year figure Ionis reported. Sources: Ionis quarterly results releases, filed as 8-K exhibits.

What is slowing the launch

Ionis's quarterly report names what has stood in the way so far.10-Q

10-QPart II, Item 1A: Risk factorsIonis Pharmaceuticals · accepted Nov. 9, 2026, 8:33 a.m. ET
For example, the TRYNGOLZA launch for sHTG is at an early stage where a majority of TRYNGOLZA prescriptions require a medical exemption. Some health care practitioners are hesitant to prescribe a newly approved medicine, like TRYNGOLZA, before formal coverage with payors is in place.
From Ionis's Form 10-Q for the quarter ended Sept. 30, 2026. The highlight is KeyVex's.

By the end of September, about 1,500 doctors and other prescribers had written Tryngolza for sHTG, Ionis said on the call. About 24% had written more than one prescription.Call Plans covering 33% of commercially insured people had added the new use to their lists of covered drugs, it said. Until coverage comes through, a program called Quick Start lets patients begin treatment.Call

Ionis says the slow start is consistent with how doctors often adopt new specialty medicines. Prescribers "want to see how a patient responds to treatment before prescribing more broadly," Kyle Jenne, its chief global product strategy officer, said on the call.Call Chief Executive Brett Monia said "demand is increasing for TRYNGOLZA."Call

The $3 billion question

In April, with its first 2026 forecast, Ionis raised its goal for Tryngolza's peak yearly sales to more than $3 billion, from more than $2 billion.8-K It kept that goal on Nov. 9.Call

Jessica Fye, an analyst at J.P. Morgan, asked on the call how long Ionis expects it will take to get there. Ionis said it had not given any view on the time to peak.Call

Ionis had $1.9 billion in cash and short-term investments at Sept. 30.8-K

Arrowhead's rival drug

Shares of Arrowhead Pharmaceuticals, which sells a rival drug, were also lower on Nov. 9, down 17% at 1:17 p.m.ARWR The company had made no SEC filing that day, and the records do not show why its stock moved.EDGAR

Arrowhead's Redemplo and Tryngolza both lower the liver's production of the same protein, called APOC3.8-K8-K The FDA approved Redemplo for FCS on Nov. 18, 2025.10-Q Patients inject it once every three months; Tryngolza is a once-monthly shot.8-K10-Q

The two companies are also in court. Ionis sued Arrowhead in September 2025, saying Redemplo infringes an Ionis patent, and Arrowhead counterclaimed that the patent is invalid or not infringed. The case is ongoing, Ionis's quarterly report says.10-Q

Arrowhead agreed on July 31 to pay $215 million for a priority review voucher, which entitles its holder to a faster FDA review of a single application, and planned to use it on its sHTG filing, its quarterly report says.10-Q On Oct. 7, it said the FDA had admitted its planned sHTG filing to a pilot program under which the filing qualifies for a six-month priority review without a voucher, so it is keeping the voucher.Release

Arrowhead says it is on schedule to file for sHTG by the end of 2026.Release It reports its results for the fiscal year that ended Sept. 30 on Nov. 12.Release

What to watch

  1. Arrowhead reports results for its fiscal year that ended Sept. 30.

  2. A final European decision on Tryngolza for sHTG, which Ionis expects in the fourth quarter of 2026 after a positive opinion from the European Medicines Agency's drug committee.

  3. Arrowhead's planned FDA filing to add sHTG to Redemplo's approved uses.

  4. Ionis's full-year results and its 2027 forecast.

The paper trail

The filings behind this story, Feb. 25 through Nov. 9, 2026.

Filed (ET)FormFilerWhat it shows
Feb. 258-KIonis2025 results: Tryngolza sold $108 million, $50 million of it in the fourth quarter.
April 298-KIonisFirst 2026 forecast for Tryngolza, $100 million to $110 million; peak sales goal raised to more than $3 billion.
June 248-KIonisThe FDA approves Tryngolza for sHTG.
July 298-KIonisSecond-quarter Tryngolza sales of $5 million; on track for the forecast and for cash-flow breakeven in 2028.
Aug. 410-QArrowheadAgreed July 31 to buy a $215 million priority review voucher for its planned sHTG filing. On Oct. 7 it said the filing no longer needs the voucher.
Aug. 48-KArrowheadExpects to file for sHTG before the end of 2026.
Nov. 9, 7:00 a.m.8-KIonisThird-quarter Tryngolza sales of $9 million; 2026 forecast cut to about $50 million.
Nov. 9, 8:33 a.m.10-QIonisThe April price cut and why; a majority of prescriptions need a medical exemption; the Arrowhead lawsuit.

Sources

13 sources, 8 of them public records

Public records

  1. Ionis Pharmaceuticals, Form 8-K, Exhibit 99.1: third-quarter 2026 resultsSEC EDGAR · Nov. 9, 2026
  2. Ionis Pharmaceuticals, Form 10-Q for the quarter ended Sept. 30, 2026SEC EDGAR · Nov. 9, 2026
  3. Ionis Pharmaceuticals, Form 8-K, Exhibit 99.1: second-quarter 2026 resultsSEC EDGAR · July 29, 2026
  4. Ionis Pharmaceuticals, Form 8-K, Exhibit 99.1: first-quarter 2026 resultsSEC EDGAR · April 29, 2026
  5. Ionis Pharmaceuticals, Form 8-K, Exhibit 99.1: fourth-quarter and full-year 2025 resultsSEC EDGAR · Feb. 25, 2026
  6. Ionis Pharmaceuticals, Form 8-K, Exhibit 99.1: FDA approval of Tryngolza for sHTGSEC EDGAR · June 24, 2026
  7. Arrowhead Pharmaceuticals, Form 10-Q for the quarter ended June 30, 2026SEC EDGAR · Aug. 4, 2026
  8. Arrowhead Pharmaceuticals, Form 8-K, Exhibit 99.1: fiscal third-quarter 2026 resultsSEC EDGAR · Aug. 4, 2026

Rules and references

  1. Arrowhead Pharmaceuticals' filings on EDGAR (none dated Nov. 9, 2026, as of that afternoon)SEC EDGAR · Nov. 9, 2026

Reporting

  1. Arrowhead Pharmaceuticals release: "Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia" (Business Wire, as reposted)Finviz · Oct. 7, 2026
  2. Arrowhead Pharmaceuticals release: "Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results" (Business Wire, as reposted)Finviz · Nov. 3, 2026
  3. "Earnings call transcript: Ionis beats Q3 2026 estimates but shares sink 28%"Investing.com · Nov. 9, 2026

Data

  1. End-of-day prices for IONS, and for SPY and QQQ on the chart (Tiingo); IONS and ARWR intraday quotes at 1:17 p.m. ET on Nov. 9 (IEX via Tiingo)KeyVex · through Nov. 9, 2026

How we got these numbers

  • Prices are end-of-day closes as traded, not adjusted for dividends; the chart ends at the Nov. 6 close, the last before the forecast cut. The Nov. 9 moves are intraday: the last IEX trade at 1:17 p.m. ET against the Nov. 6 close (Ionis $29.95 against $39.42; Arrowhead $48.16 against $58.16), via Tiingo. They are not the day's closing moves. The S&P 500 and Nasdaq 100 lines follow SPY and QQQ, also as traded. The chart's Filings switch shows a selection of KeyVex filing markers for Ionis, not every filing, and not only those tied to this story; it starts off.
  • Quarterly Tryngolza sales are U.S. net product sales as Ionis printed them, rounded to the million, from each quarter's results release (2025 quarters from the prior-year columns of the 2026 releases, and the fourth quarter from the full-year release). Because each is rounded, the four 2025 quarters add to $107 million, against the $108 million Ionis reported for the year.
  • "Under a fifth" compares $9 million in the third quarter of 2026 with $50 million in the fourth quarter of 2025.
  • Quotes from Ionis's Nov. 9 earnings call come from the transcript Investing.com published that morning.

How KeyVex News works. Our stories are researched, drafted and checked with AI tools from public records. Every figure is checked against the filing it cites, and each story passes a final review before publication. Corrections are made in place and noted at the top of the story.

KeyVex News reports on public records. Nothing here is investment advice or a recommendation to buy or sell any security. Close prices from Tiingo.com.

The image shown with this story is AI-generated.

Read next

View all news